BMJ Open HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional study

Geane Felix De Souza,^{1,2} Howard Lopes Ribeiro Jr,^{1,2} Juliana Cordeiro De Sousa,^{1,2} Fabíola Fernandes Heredia,² Rivelilson Mendes De Freitas,³ Manoel Ricardo Alves Martins,⁴ Romélia Pinheiro Gonçalves,⁵ Ronald Feitosa Pinheiro,^{2,4} Silvia Maria Meira Magalhães^{2,4}

To cite: De Souza GF, Ribeiro HL, De Sousa JC, *et al.* HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional study. *BMJ Open* 2015;**5**:e006048. doi:10.1136/bmjopen-2014-006048

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2014-006048>).

Received 4 July 2014
Revised 10 December 2014
Accepted 11 December 2014

CrossMark

For numbered affiliations see end of article.

Correspondence to
Dr Silvia Maria Meira Magalhães; silviamm@ufc.br

ABSTRACT

Objective: A relation between transfusional IOL (iron overload), HFE status and oxidative damage was evaluated.

Design, setting and participants: An observational cross-sectional study involving 87 healthy individuals and 78 patients with myelodysplastic syndromes (MDS) with and without IOL, seen at University Hospital of the Federal University of Ceará, Brazil, between May 2010 and September 2011.

Methods: IOL was defined using repeated measures of serum ferritin ≥ 1000 ng/mL. Variations in the HFE gene were investigated using PCR/restriction fragment length polymorphism (RFLP). The biomarkers of oxidative stress (plasmatic malonaldehyde (MDA), glutathione peroxidase (GPx) and superoxide dismutase (SOD)) were determined by spectrophotometry.

Results: The HFE gene variations were identified in 24 patients (30.77%) and 5 volunteers (5.74%). The H63D variant was observed in 35% and the C282Y variant as heterozygous in 5% of patients with MDS with IOL. One patient showed double heterozygous variant (C282Y/H63D) and serum ferritin of 11 649 ng/mL. In patients without IOL, the H63D variant was detected in 29.34%. Serum MDA levels were highest in patients with MDS with IOL, with a significant difference when compared with patients without IOL and healthy volunteers, pointing to the relationship between IOL and oxidative stress. The GPx and SOD were also significantly higher in these patients, indicating that lipid peroxidation increase was followed by an increase in antioxidant capacity. Higher ferritin levels were observed in patients with HFE gene variation. 95.7% of patients with MDS with the presence of HFE gene variations had received more of 20 transfusions.

Conclusions: We observed a significant increase in MDA levels in patients with MDS and IOL, suggesting an increased lipid peroxidation in these patients. The accumulation of MDA alters the organisation of membrane phospholipids, contributing to the process of cellular degeneration. Results show that excess iron

Strengths and limitations of this study

- Oxidative stress and its effects on cellular biology, DNA damage and carcinogenesis have become a hot topic in MDS research. The parameters evaluated in this study are important indicators the oxidative status and pointed to the relationship between IOL and oxidative stress in patients with MDS.
- Our study found iron overload, a significant prognostic factor for overall survival in lower risk MDS patients. Worse clinical outcomes, including cardiac, hepatic and endocrine dysfunction, leukemic progression and infectious complications have also been associated with iron overload.
- Despite its limitation as an acute phase reactant, serum ferritin remains a valuable tool for diagnosis and monitoring iron overload, given its wide availability, low cost and well standardized measures. More prolonged follow-up can confirm our findings, how the ferritin levels higher in all groups of patients and healthy volunteers with gene HFE mutation.
- The results of this study suggested that the presence of HFE gene variations, can be directly correlated with the need for blood transfusion, which can induce to iron overload. There was a direct relationship between oxidative stress markers and iron overload, but no was observed significant effect with the HFE gene variation and the oxidative stress markers in patients with MDS.
- The number of cases evaluated herein may not be representative of the population, and a study with larger population to confirm these results is warranted.

intensifies the process of cell damage through oxidative stress.

Trial registration number: Local Ethics Committee (licence 150/2009).

INTRODUCTION

Myelodysplastic syndromes (MDS) comprise a heterogeneous range of haematopoietic diseases characterised by bone marrow failure and a variable propensity to evolve into acute myeloid leukaemia. Most patients have anaemia at some point in the course of the disease and many develop transfusion dependence and consequent iron overload (IOL), considered to be a negative independent prognostic factor associated with a higher risk of leukaemic transformation and shorter survival.¹ The pathogenesis of MDS is complex and involves the haematopoietic stem cells, bone marrow microenvironment and the interaction between them. Recently, attention has been focused on oxidative stress and its negative effect on self-renewal and the number of haematopoietic stem cells. Nuclear and mitochondrial DNA can be directly damaged by hydroxyl radicals resulting in genomic instability contributing to disease progression.²⁻³ Excess of iron due to multiple transfusions is toxic through the production of free radicals derived from activated oxygen species, which eventually form hydroxyl radicals from superoxide or hydrogen peroxide resulting in organ dysfunction.⁴ Hereditary haemochromatosis (HH) is an autosomal recessive disorder characterised by the enhanced intestinal absorption of dietary iron associated with the presence of variations in the HFE gene located in the short arm of chromosome 6.⁵ The gene variations result in a tyrosine substitution by cysteine residue at position 282 (C282Y allele), exchange of histidine to aspartic acid at amino acid position 63 (H63D allele) and substitution of cysteine for serine at amino acid position 65 (S65C allele). Patients with HH are most frequently either homozygous for C282Y or compound heterozygous for C282Y/H63D.⁶ HFE gene variants correlate with body iron levels and have shown association with cancer risk including childhood acute lymphoblastic leukaemia (ALL).⁷ Increased IOL and iron-mediated oxidative stress may be directly involved in the pathogenesis of MDS. We hypothesise if the presence of HH gene variations in homozygous as well as heterozygous forms could contribute to a significantly higher rate of iron accumulation in the context of transfusion dependence.⁸ The aim of this study was to evaluate the presence of variations in the HFE gene and the oxidative status in patients with MDS with IOL and compare these findings with those of patients without IOL and healthy individuals.

MATERIALS AND METHODS

This observational cross-sectional study included 78 sequential adult patients with MDS, 58 without and 20 with IOL, seen at University Hospital of the Federal University of Ceará, Brazil, between May 2010 and September 2011. The disease was classified according to the French American British (FAB) and/or WHO criteria⁹ and the International Prognostic Scoring System (IPSS).¹⁰ IOL was defined using repeated measures of

serum ferritin ≥ 1000 ng/mL. The control group was composed of 87 healthy volunteers. All patients were included at diagnosis and all samples were collected prior to any treatment or chelation therapy. Those with some conditions known to influence oxidative stress biomarkers were excluded (pregnancy, alcoholism, smoking, alcoholism, use of vitamins, chronic renal failure and hepatitis).

DNA EXTRACT, GENOTYPING AND PCR-RFLP ANALYSIS

Genomic DNA was extracted from peripheral blood using the method described by Biometrix Diagnostica/DNA Biopur. HFE genotyping for the C282Y, H63D and S65C mutations was performed using the PCR/restriction fragment length polymorphism (PCR-RFLP). The protocol was the same as that described by Feder¹¹ and Simonsen.¹² Fragments of 296bp and 145bp for the wild alleles (282CC), of 296bp, 116bp and 29bp for the homozygous allele (282YY) and of 296bp, 145bp, 116bp and 29bp for the heterozygous allele (282CY) were used for identification. Only one fragment of 496bp was used for the homozygous allele (63DD) and 496bp, 352bp and 144bp were used for the heterozygous allele (63HD). The fragments 352bp and 144bp corresponded to the wild allele (63HH). The fragments of 274bp, 147bp, 69bp and 6bp were used to detect the wild allele (65SS), the fragments 274bp, 216bp, 147bp, 69bp and 6bp for the heterozygous allele (65SC) and the fragments 274bp, 216bp and 6bp for the allele mutant (65CC) (figure 1).

HAEMATOLOGICAL PARAMETERS, IRON AND OXIDATIVE STATUS

All samples were obtained at least 8 days following the latest transfusion. Peripheral blood samples collected with EDTA were used for haematological analysis and evaluation of glutathione peroxidase (GPx) and superoxide dismutase (SOD), or collected with heparin for malonaldehyde (MDA) evaluation. Serum iron and transferrin saturation were assayed using standard techniques (Olympus AU 400e—Siemens) and serum ferritin was measured by enzyme immunoassay (Abbott Laboratory). The MDA analysis was based on its reaction with thiobarbituric acid (TBARS) at a temperature of 100°C.¹³ Antioxidant activity was evaluated using the kit Ransel for GPx and kit Ransod for SOD.

STATISTICAL ANALYSIS

The χ^2 test was used to compare the frequency of polymorphisms in the HFE gene and to compare the relationship between the number of units transfused in patients with MDS with HFE variant carriers and non-variants. The analysis of variance (ANOVA) test was used (along with Tukey's post hoc test) to compare the average values and the SD. Significant differences between the three groups were tested by two-way ANOVA and the t-Student-Newman-Keuls as post hoc

Figure 1 PCR-RFLP (restriction fragment length polymorphism) blots of the C282Y, H63D and S65C mutations. Six patients are represented. M: DNA marker 100bp (Invitrogen). Band sizes are indicated on the left and right of the panel. Homozygous allele of C282Y (fragments 296bp, 116bp, 29bp); heterozygous allele of C282Y (fragments 296bp, 145bp, 116bp, 29bp); homozygous allele of H63D (only fragment of 496bp); heterozygous allele of H63D (fragments 496bp, 352bp and 144bp). Wild allele S65C (fragments of 274bp, 147bp, 69bp and 6bp).

test or by Kruskal-Wallis test followed by Dunns test as appropriate. Significant differences between the patients with and without IOL were tested by two-way test t-Student and Mann-Whitney. Statistical analysis was performed using the GraphPrism program (V.5.01). The level of significance was set at $p < 0.05$.

RESULTS

Median age of the control group (group 1), patients with MDS without IOL (group 2) and patients with IOL (group 3) were 75, 63.8 and 68.9 years, respectively. Patients with IOL received an average of 42.8 transfusions and had a mean serum ferritin level of 2880 ng/mL. Patient characteristics are shown in table 1.

Of the 78 patients, 24 (30.77%) were identified as having at least one variation in the *HFE* gene, being 14 (58.33%) in male patients. Only 5 volunteers (5.75%) presented with gene variation. In the patients with MDS with IOL, the H63D variant was observed as homozygous in 5% (1/20), as heterozygous in 30% (6/20), and the C282Y variant was detected as heterozygous in 5% (1/20). In one patient, a double heterozygous variant was detected (C282Y/H63D). In the group of patients without IOL, the H63D variant was detected as homozygous in 5.2% (3/58) and as heterozygous in 24.14% (14/58). No S65C mutation was detected. The distribution of the genotypes according to variation type is shown in table 2 and figure 2.

The allele frequency for the H63D allele was 3.05%, 14.66% and 17.50% in the control group, patients without IOL and patients with IOL, respectively. For the C282Y allele, the frequency was 2.5%, detected only in patients with IOL.

The genotype frequencies of the *HFE* variant in controls and in patients with and without IOL were significantly different ($p = 0.0013$ and 0.0002 , respectively), higher in patients with and without IOL. However, no significant difference was observed between these two groups of patients ($p = 0.6345$).

Seven patients with IOL (35%) were identified with mutation in the *HFE* gene. Of three mutations in the gene *HFE* (C282Y; H63D; S65C) evaluated, one of our cases presented two variants (C282Y; H63D) and the highest level of serum ferritin (11 649 ng/mL). Double variant has a higher risk of iron accumulation. Initial investigation showed haemoglobin of 5 g/dL, white cell count $0.641 \times 10^9/L$ and platelet count $2 \times 10^9/L$. Cytogenetic analysis demonstrated a complex karyotype (42XY, -18, -19, -21, -22/46, XY). At follow-up, the patient presented with remarkable pancytopenia with transfusion dependence. After transfusion of 24 units of packed red blood cells (RBCs), serum ferritin was as high as 11 649 ng/mL, a figure confirmed later on. The patient was treated with decitabine 20 mg/m²/day for 5 days and died soon after finishing the first cycle.

The ferritin levels were higher in all groups of patients with *HFE* gene variation (table 3). Healthy volunteers with *HFE* gene variation also showed a significant increase in ferritin levels ($p = 0.0054$).

The majority of the patients with MDS (87.5%) who had the non-variant *HFE* gene received less than 10 transfusion units. However, the number of patients with MDS with mutations in the *HFE* gene (95.7%) received more than 20 transfusions. The presence of *HFE* gene variations in homozygous as well as heterozygous forms was correlated with the need for blood transfusion (χ^2 test: 42.92, 9; $p < 0.0001$).

Patients with IOL showed a significant increase in plasma MDA when compared with all groups ($p < 0.0001$). Levels of MDA were higher in the IOL group compared with the group without IOL. When MDA levels were compared according to the presence of

Table 1 Clinical and laboratory characteristics of patients with myelodysplastic syndromes (MDS) with and without iron overload (IOL) and healthy volunteers

Variables	Healthy volunteers n=87	MDS without IOL n=58	MDS with IOL n=20	p Value
Demographics				
Gender (male/female)	9/78	31/27	9/11	
WHO classification				
Refractory anaemia (RA)		6	—	
RA with ringed sideroblasts (RARS)		5	5	
Refractory cytopenia with multilineage dysplasia (RCMD)		36	12	
RA with excess of blasts—I		2	—	
RA with excess of blasts—II		4	2	
Secondary MDS		5	1	
IPSS risk group				
Low		12	3	
Intermediate I		24	7	
Intermediate 2		4	1	
High		1	—	
Unknown		12	8	
Blood counts (mean±SD)				
Haemoglobin (g/dL)	13.36±0.959	9.62±3.076	6.29±1.805	<0.0001*,†,‡
Neutrophils (mm ³)	3765±1083	1805±1452	1823±1716	<0.0001*,†
Platelets (mm ³)	250 356±59 277	135 102±134 584	124 089±125 786	<0.0001*,†,‡
Iron profile (mean±SD)				
Serum iron (µg/dL)	87.41±28.55	107.6±51.12	195.1±70.21	<0.0001*,†,‡
Serum ferritin (ng/mL)	140.9±96.75	297.2±223.8	28 800±26 820	<0.0001*,†,‡
Transferrin saturation (%)	32.37±8.819	44.66±23.22	79.70±21.24	<0.0001*,†,‡

*p Value for comparison between MDS without IOL and control group.

†p Value for comparison between MDS with IOL and control group.

‡p Value for comparison between MDS with IOL and MDS without IOL.

MDS, myelodysplastic syndromes; IOL, iron overload; IPSS, International Prognostic Scoring System; WHO, World Health Organization.

the HFE gene variant for patients without IOL, no statistically significant difference was observed, although there was a trend of increase in the concentration of MDA in the group with HFE variant ($p=0.2789$; table 3).

The antioxidant enzymes, SOD and GPx, were significantly higher in patients with IOL when compared with patients without IOL ($p=0.0289$ and 0.0267 , respectively). GPx activity was also significantly higher in patients with HFE gene variation. However, in the group of patients with no IOL, no significant difference was observed between mutated and non-mutated cases (table 3).

DISCUSSION

Anaemia is the most frequently observed cytopenia in patients with MDS. As elderly patients are especially

vulnerable to anaemia-related comorbidities, most patients require RBC transfusions as a supportive care. Excess iron, due to multiple transfusions (>20 units of packed red cells), is toxic through the production of free radicals derived from activated oxygen species, resulting in organ dysfunction and oxidative stress.¹⁴ In the IOL group, we detected an average of over 40 blood transfusions. In Brazil, patients with transfusional iron overload must wait for up to 1 year for an interview by a haematologist. This may explain the high number of patients with increased serum ferritin at diagnosis.

A few studies have reported a positive correlation between IOL and increased production of reactive oxygen species in MDS,^{15 16} including a recent report by our group in which the preliminary results of some patients have been mentioned.¹⁷ Recently, improvement of iron-

Table 2 HFE genotype frequency distribution according to polymorphism type

Genotype (n=165)	WT/C282Y, n (%)	H63D/H63D, n (%)	H63D/WT, n (%)	C282Y/H63D, n (%)	WT/WT, n (%)
Healthy volunteers (87)			5 (5.75)		82 (94.25)
MDS without IOL (58)		3 (5.2)	14 (24.1)		41 (70.7)
MDS with IOL (20)	1 (5.0)*	1 (5.0)	5 (25.0)	1 (5.0)	13 (65.0)

*This patient had double heterozygous variant (C282Y/H63D).

IOL, iron overload; MDS, myelodysplastic syndromes; WT, wild-type allele.

Figure 2 Number of individuals analysed and percentage of HFE gene mutations (C282Y; H63D) in the groups studied.

mediated oxidative damage after treatment with deferasirox has been demonstrated by several authors.^{18–20}

In this study, MDA values were significantly higher in patients with IOL when compared with patients without IOL and this was supposed to be independent of the polymorphism in the HFE gene, once the presence of the HFE variant did not show the same effect in patients without IOL. The presence of mutation in the group without IOL did not directly affect the parameters of lipid peroxidation. The antioxidant enzymes were also significantly higher in patients IOL, indicating that lipid peroxidation increase was followed by an increase in antioxidant capacity. Although current understanding of these effects is still waiting for more evidence, it is consensual that IOL should be monitored and managed in a selected group of patients based on risk stratification, life expectancy, iron burden and ongoing transfusion need.

According to most published reports worldwide, the C282Y variant corresponds to 80% of cases with clinical manifestations of HH and the remaining patients are mostly compound heterozygous (C282Y/H63D) for the

HFE gene.^{21–22} In the present study, the C282Y allele frequency, observed only in patients with IOL, was similar to that previously reported in other haematological diseases and IOL.

The genotypic frequency observed for the C282Y/H63D compound heterozygote was in agreement with the data reported for the American population.²³ Double heterozygote has a higher risk of iron accumulation as was presented in one of our cases.

Our findings regarding the frequency of HFE gene variants were different from those reported by Nearman *et al* that compared patients with MDS with refractory anaemia and healthy controls but were similar to the results obtained by Varkonyi *et al* who reported a significant increase in patients with MDS compared with the control group.^{24–25} List *et al* analysed 94 patients with MDS for HFE mutations and detected 25.5% of patients heterozygous for H63D,²⁶ a figure similar to the overall frequency observed in this study. However, the frequency of the H63D allele (3.05%) in the control group was lower than that reported for Brazilian blood donors: 2.1% and 13.4% for C282Y and H63D, respectively.^{27–28}

It would be reasonable to hypothesise that the presence of HFE gene variation contributes to increased serum MDA values. However, Parkkila *et al*²⁹ demonstrated that HFE gene variation did not account for additional harm in patients with transfusional IOL with acute myeloid leukaemia. In the present report, statistical analysis showed no significant difference when patients with and without gene variation were compared. In the specific group of patients with MDS, the increased absorption of iron secondary to a decrease in the hepcidin level and the transfusional iron loading were the main factors of IOL, probably overcoming the effect of the presence of the HFE variant.

The results of this study suggested that the presence of HFE gene variations in homozygous and heterozygous forms can be directly correlated with the need for blood transfusion, which can induce IOL. Increased MDA

Table 3 Values of ferritin, MDA, SOD and GPx in the groups according to the presence of mutation HFE gene

Group	Parameters Mean±SD	HFE gene no mutation n=41 (70.7%)	HFE gene mutation n=17 (29.3%)	p Value
MDS without IOL (n=58)	FRT (ng/dL)	205.3±139.7	518.6±236.4	<0.0001*
	MDA (µM)	9.592±3.073	10.91±4.651	0.2789
	SOD (Ug/Hb)	3497±603.8	3590±563.1	0.6376
	GPx (Ug/Hb)	76.46±17.73	91.16±7.489	0.0046*
Group	Parameters Mean±SD	HFE gene no mutation n=13 (65%)	HFE gene mutation n=7 (35%)	p Value
MDS with IOL (n=20)	FRT (ng/dL)	1883±1236	4731±3684	0.0189†
	MDA (µM)	13.30±1.227	14.85±1.195	0.0273†
	SOD (Ug/Hb)	4850±420.60	5334±310.10	0.0289†
	GPx (Ug/Hb)	144.50±16.95	165.40±15.27	0.0267†

*p Value for comparison between MDS without IOL and with mutation versus MDS without IOL and HFE gene no mutation.

†p Value for comparison between MDS with IOL and with mutation versus MDS with IOL and HFE gene no mutation.

FRT, ferritin; GPx, glutathione peroxidase; IOL, iron overload; MDA, malonaldehyde; MDS, myelodysplastic syndromes; SOD, superoxide dismutase.

levels in patients with MDS and IOL suggests elevated lipid peroxidation and that excess iron intensifies the process of cell damage through oxidative stress. However, the number of cases evaluated may not be representative and larger studies are necessary to confirm these data.

Author affiliations

¹Post-Graduate Program in Medical Science, Department of Clinical Medicine, Federal University of Ceara, Fortaleza, Ceara, Brazil

²Cancer Cytogenomic Laboratory, Federal University of Ceara, Fortaleza, Ceara, Brazil

³Department of Pharmacia, Federal University of Piauí, Teresina, Piauí, Brazil

⁴Department of Clinical Medicine, Federal University of Ceara, Fortaleza, Ceara, Brazil

⁵Department of Clinical and Toxicological Analysis, Federal University of Ceara, Fortaleza, Ceara, Brazil

Twitter Follow Geane de Souza at @geanefelix@ig.com.br

Acknowledgements This work was supported by CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) e FUNCAP (Fundação de Amparo à Pesquisa do Estado do Ceará).

Contributors GFdS and SMMM contributed to conception and design. GFdS, SMMM, RFP, RPG and RMdF provided the study materials or patients. HLRJ, JCdS and FFH were involved in collection and assembly of data. GFdS, SMMM and MRAM were involved in data analysis and interpretation. GFdS and SMMM were involved in manuscript writing. All authors approved the final manuscript.

Competing interests None.

Patient consent Obtained.

Ethics approval The project received approval from the local ethic committee (0150.12.09).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Malcovati L, Della Porta MG, Pascutto C, *et al.* Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. *J Clin Oncol* 2005;23:7594–603.
2. Ghoti H, Amer J, Winder A, *et al.* Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndromes. *Eur J Haematol* 2007;79:463–7.
3. Rassool F, Gaymes TJ, Omidvar N, *et al.* Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? *Cancer Res* 2007;67:8762–71.
4. Kohgo Y, Ikuta K, Ohtake T, *et al.* Body iron metabolism and pathophysiology of iron overload. *Int J Haematol* 2008;88:7–15.
5. Guerreiro RJ, Bras JM, Santana I, *et al.* Association of HFE common polymorphisms with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. *BMC Neurol* 2006;6:24.
6. Beutler E. Hemochromatosis: genetics and pathophysiology. *Annu Rev Med* 2006;57:331–47.
7. Kennedy AE, Kamdar KY, Lupo PJ, *et al.* Examination of HFE association with childhood leukemia risk and extension to other iron regulatory genes. *Leuk Res* 2014;38:1055–60.
8. Nearman ZP, Szpurka H, Serio B, *et al.* Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. *Am J Hematol* 2007;82:1076–9.
9. Vardiman JW, Harris NL, Brunning RD. The World Health (WHO) classification of the myeloid neoplasms. *Blood* 2002;100:2292–302.
10. Greenberg P, Cox C, Lebeau MM, *et al.* International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* 1997;89:2079–88.
11. Feder JN, Gnirke A, Thomas W, *et al.* A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* 1996;13:399–408.
12. Simonsen K, Dissing J, Rudbeck L, *et al.* Rapid and simple determination hereditary haemochromatosis mutation by multiplex PCR-SSCP: detection of a new polymorphic mutation. *Ann Hum Genet* 1999;63:193–7.
13. Draper HH, Hadley M. Malonaldehyde determination as index of lipid peroxidation. *Methods Enzymol* 1990;186:421–31.
14. Gattermann N, Rachmilewitz EA. Iron overload in MDS pathophysiology, diagnosis and complications. *Ann Hematol* 2011;90:1–10.
15. Saigo K, Takenokuchi M, Hiramatsu Y, *et al.* Oxidative stress levels in myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. *J Int Med Res* 2011;39:1941–5.
16. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. *Int J Hematol* 2003;77:342–50.
17. De Souza GF, Barbosa MC, Santos TE, *et al.* Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. *J Clin Pathol* 2013;66:996–8.
18. Kikuchi S, Kobune M, Iyama S, *et al.* Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. *Free Radic Biol Med* 2012;53:643–8.
19. Ghoti H, Fibach E, Merkel D, *et al.* Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. *Haematologica* 2010;95:1433–4.
20. Saigo K, Kono M, Takagi Y, *et al.* Deferasirox reduces oxidative stress in patients with transfusion dependency. *J Clin Med Res* 2013;5:57–60.
21. Santos PCJL, Krieger JE, Pereira AC. Molecular diagnostic and pathogenesis of hereditary hemochromatosis. *Int J Mol Sci* 2012;13:1497–511.
22. Beutler E. Iron absorption in carriers of the C282Y hemochromatosis mutation. *Am J Clin Nutr* 2004;80:799–800.
23. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. *Gastroenterology* 2010;139:393–408.
24. Varkonyi J, Demeter J, Tordai A, *et al.* The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome. *Ann Hematol* 2006;85:869–71.
25. Varkonyi J, Tarkovacs G, Karadi I, *et al.* High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. *Acta Haematol* 2003;109:64–7.
26. List AF, Baer MR, Steensma DP, *et al.* Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. *J Clin Oncol* 2012;30:2134–9.
27. Terada CT, Santos PC, Cançado RD, *et al.* Iron deficiency and frequency of HFE C282Y gene mutation in Brazilian blood donors. *Transfus Med* 2009;19:245–51.
28. Viana-Baracioli LM, Tukamoto Junior NC, Ricci Junior O, *et al.* Comparison of oxidative stress and the frequency of polymorphisms in the HFE gene between hemoglobin S trait blood donors and sickle cell disease patients. *Genet Mol Res* 2011;10:3446–54.
29. Parkkila S, Niemelä O, Britton RS, *et al.* Molecular aspects of iron absorption and HFE expression. *Gastroenterology* 2001;121:1489–96.